United States Patent 5,478,847: Scope, Claim Analysis, and US Landscape
US Patent 5,478,847 claims a method of inhibiting bone loss / bone resorption by administering a compound of formula I (structure not reproduced in the excerpt you provided) at specific daily dose ranges (about 50 to 150 mg/day), including salt forms, with claim fallbacks that narrow to osteoporosis, post-menopausal females, prophylaxis, specific daily dosages, and hydrochloride salt.
What matters commercially is that the claim set is drafted to cover treatment and prevention of bone loss, not just a composition. That structure typically supports enforceability against label-faithful dosing and may also affect generic carve-outs, because method claims can reach off-patent product use if the use matches the claim parameters.
What is the claim scope in US 5,478,847?
Core independent claim (Claim 1): breadth and enforceability hooks
Claim 1 is a classic dependent-method ladder anchor:
- Claim type: method of treatment/prevention
- Treatment goal: “inhibiting bone loss or bone resorption”
- Patient population: “a human in need thereof”
- Active: “a compound of formula I” or “pharmaceutically acceptable salt or solvate”
- Dose: “about 50 to 150 mg/day”
Scope characteristics
- Indication is functional, not mechanistic. The claim does not require a biomarker definition or explicit MOA. It only requires that the method inhibits bone loss/bone resorption, which is often shown clinically.
- Population is essentially any “human in need.” This is broad and can capture both men and women, treatment-naïve and previously treated patients, and both primary and secondary bone loss conditions as long as bone loss/bone resorption inhibition is established.
- Dose range is a key limiting parameter. Any product method outside the claimed daily exposure may reduce literal infringement risk, depending on doctrine of equivalents and how “about” is interpreted.
- Formulation flexibility is limited only by the chemical definition. The claim expressly includes “salt or solvate,” so a reformulation that stays within the salt/solvate universe remains within scope.
Dependent claims (2–12): narrowing dimensions
Claims 2–12 do not create separate drug technologies. They carve narrower patient and use scenarios, and they lock in specific dose points and one named salt.
Indication and demographics
- Claim 2: patient “diagnosed as suffering from osteoporosis”
- Claim 3: post-menopausal female
- Claim 4: male
These are incremental narrowing layers. They matter when designing launch labels, post-marketing claims, and litigation positions because they can create multiple overlapping infringement theories for different subpopulations.
Treatment vs prevention
- Claim 5: prophylactically (prevention use)
This is important because prevention dosing frequently differs from treatment dosing, and method claims that expressly include prophylaxis are more likely to catch preventive regimens.
Dose narrowing (explicit endpoints)
- Claim 6: “about 60 to about 150 mg/day”
- Claim 7: 60 mg/day
- Claim 8: 75 mg/day
- Claim 9: 100 mg/day
- Claim 10: 125 mg/day
- Claim 11: 150 mg/day
These claims do two things:
- They preserve coverage even if a competitor avoids the “about 50 to 150” range by selecting a dose that still falls within the narrower “about 60 to about 150” or hits an exact dosage point.
- They support enforcement against a product label using a standard fixed-dose regimen.
Salt specificity
- Claim 12: compound is the hydrochloride salt
This provides an additional claim theory for a competitor whose active is within the same chemical family but implemented as a hydrochloride salt.
What are the practical claim coverage boundaries (dose, population, and form)?
Dose coverage map
From the claim text, the day-dose boundaries are layered:
| Claim ID |
Dose limitation in claim |
Coverage implication |
| 1 |
about 50 to 150 mg/day |
Baseline dose range |
| 6 |
about 60 to about 150 mg/day |
Removes the 50–60 mg/day slice |
| 7 |
60 mg/day |
Exact regimen |
| 8 |
75 mg/day |
Exact regimen |
| 9 |
100 mg/day |
Exact regimen |
| 10 |
125 mg/day |
Exact regimen |
| 11 |
150 mg/day |
Exact regimen |
Strategic litigation and design impact
- A dose selection that lands between 50 and 60 mg/day may avoid Claim 6 but can still be inside Claim 1 because Claim 1 includes about 50 to 150.
- A dose outside 150 mg/day is the cleanest way to escape the stated dose ceiling, though “about” can broaden interpretation at the margin.
- If a competitor uses a fixed dose at 75/100/125 mg/day (common in once-daily regimens), they face direct infringement risk under Claims 8–10 if other elements match.
Population scope
The claim set covers:
- Any human “in need” (Claim 1)
- Osteoporosis patients (Claim 2)
- Post-menopausal females (Claim 3)
- Males (Claim 4)
- Prophylactic use (Claim 5)
This structure supports multiple overlapping infringement theories depending on the label and real-world prescribing.
Compound scope
The claim set covers:
- Any “compound of formula I”
- Pharmaceutically acceptable salts and solvates (Claim 1)
- Hydrochloride salt specifically (Claim 12)
This is a broad chemical capture approach. It typically constrains design-around efforts because competitors cannot avoid simply by switching salt form if the alternative salt still qualifies as “pharmaceutically acceptable” under Claim 1, or if it is not hydrochloride under Claim 12.
What does the claim set imply about enforceability and litigation posture?
1) Method claim structure favors label-based proof
Because the claims are method-of-use, a patent holder typically relies on:
- the accused product’s approved labeling or promotional materials, and
- actual prescribing patterns that match the claimed dose and indication.
The presence of explicit dosages (60, 75, 100, 125, 150 mg/day) is a strong fit for label dosing and fixed-dose tablets/capsules.
2) “About” dosing supports a range-based infringement theory
Claims use “about,” so the patentee can argue for infringement at slightly off nominal doses, especially if the accused dosing produces comparable systemic exposure.
3) Prophylaxis inclusion increases risk for preventive osteoporosis products
Many markets split into preventive vs treatment dosing. Claim 5 explicitly includes prophylaxis, so prevention indications do not automatically escape infringement.
4) Hydrochloride salt claim supports enforcement even when competitors pick salt forms
Even if a competitor uses a different salt to argue non-infringement against general “salt” language, Claim 12 gives a specific anchor for hydrochloride-based products.
How does the claim landscape typically read in the US for this type of patent?
Without external bibliographic data (filing date, assignee, specification disclosure, continuation/patent family members), the landscape can only be characterized structurally based on the claim set you provided. For US drug patents with dosing-method claims in bone loss indications, the practical US landscape commonly includes:
- Related composition and formulation patents in parallel (covering the compound itself, salts, polymorphs, or sustained-release forms)
- Related method-of-use patents that vary dosing, patient subgroups, or prophylaxis vs treatment
- Combination therapy patents if bone-loss drug candidates were later combined with calcium/vitamin D, estrogenic therapy, or antiresorptives
- Regulatory exclusivities (not the patent itself) that affect timing of generic entry even after a method patent expires, though the method claims are the enforcement lever
Within this family type, Claim 1 is the “umbrella,” while Claims 2–12 are “coverage hedges”:
- indication narrowing (osteoporosis)
- demographic narrowing (post-menopausal female; male)
- use setting (prophylactic)
- dosing tightening (exact mg/day values)
- salt form specificity (hydrochloride)
That is a typical architecture to reduce design-around flexibility.
What would be the likely “most sensitive” infringement targets?
Based solely on the claim language, the most infringement-sensitive scenarios are:
- Once-daily fixed dosing at 75 mg/day, 100 mg/day, or 125 mg/day for osteoporosis or bone resorption inhibition, including preventive regimens.
- Dosing between ~60 and 150 mg/day when used to inhibit bone loss/bone resorption in diagnosed osteoporosis patients.
- Products where the active ingredient is delivered as the hydrochloride salt, especially if the label supports osteoporosis treatment or prevention at a covered daily dose.
What is the scope of design-arounds implied by the claims?
From the claim constraints alone, the main design-arounds are constrained:
- Avoid covered dose ranges: the claims cover about 50 to 150 mg/day and also lock in about 60 to about 150 mg/day plus exact dose points.
- Avoid hydrochloride: Claim 12 targets hydrochloride, but Claim 1 still covers other pharmaceutically acceptable salts/solvates.
- Avoid prophylaxis labeling: Claim 5 includes prophylaxis, but Claim 1 already covers “human in need” and may reach treatment even without explicit osteoporosis diagnosis.
Because Claim 1 is broad on patient and indication (functional outcome), design-around would have to be credible on dose/exposure and on whether the administered method meets the functional outcome claim.
Key Takeaways
- US 5,478,847 claims a method of inhibiting bone loss/bone resorption using a compound of formula I (and salts/solvates), dosed about 50 to 150 mg/day.
- The dependent claims build multiple enforcement paths: osteoporosis, post-menopausal females, males, prophylaxis, and multiple fixed daily doses (60, 75, 100, 125, 150 mg/day).
- Hydrochloride salt is explicitly claimed (Claim 12), while Claim 1 already covers other pharmaceutically acceptable salts/solvates.
- The highest-risk use patterns are osteoporosis treatment or prevention at 60–150 mg/day, especially 75/100/125 mg/day regimens.
FAQs
1) Does Claim 1 require a specific mechanism of action?
No. It requires only that the administered method inhibits bone loss or bone resorption.
2) What dosing is explicitly covered as fixed regimens?
60, 75, 100, 125, and 150 mg/day.
3) Is prophylaxis covered?
Yes. Claim 5 explicitly includes prophylactic administration.
4) Does the patent cover both men and women?
Yes. Claim 3 covers post-menopausal females and Claim 4 covers males.
5) Is hydrochloride salt specifically claimed?
Yes. Claim 12 specifies the compound as the hydrochloride salt.
References
No external sources were provided in the prompt beyond the claim text excerpt, so no citations can be generated.
